Enterprise Value

173.5M

Cash

31.53M

Avg Qtr Burn

-15.99M

Short % of Float

0.86%

Insider Ownership

0.00%

Institutional Own.

11.54%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Lanifibranor (Pan-PPAR) Details
Liver disease, Non-alcoholic steatohepatitis , Fatty liver disease

Phase 3

Data readout

Lanifibranor (Pan-PPAR) Details
Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes

Phase 2

Update

Lanifibranor + empagliflozin Details
Non-alcoholic steatohepatitis , Fatty liver disease, Liver disease, Type 2 diabetes

Phase 2a

Data readout

Cedirogant (ABBV-157) (60RORy) Details
Psoriasis, Kidney cancer, Carcinoma

Failed

Discontinued

Odiparcil (GAG) Details
Rare diseases, Rare genetic disease, Mucopolysaccharidoses, Mucopolysaccharidosis type IV, Genetic disorder

Failed

Discontinued